Stock Quote
NASDAQBSTC

BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering

PRNewswire-FirstCall
LYNBROOK, N.Y.
Jun 10, 2008

BioSpecifics Technologies Corp. (OTC BB BSTC.OB-News) today announced that it sold an aggregate of 100,000 unregistered shares of its common stock priced at $15 per share for aggregate proceeds to BioSpecifics of $1,500,000. The shares were purchased by certain private investors on June 9, 2008. The shares were sold in a company managed PIPE transaction at a premium over the market price.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and licensed injectable collagenase for three clinical indications. It has a development and licensing agreement with Auxilium Pharmaceuticals, Inc. for clinical indications in Dupuytren's disease, Peyronie's disease and frozen shoulder (adhesive capsulitis).

                     BioSpecifics' main website is at
                       http://www.biospecifics.com/

           its Dupuytren's Disease patient discussion forum at
               http://www.biospecifics.com/forum/index.html

          and its Peyronie's Disease patient discussion forum at
              http://www.biospecifics.com/forum/index2.html

SOURCE: BioSpecifics Technologies Corp.

CONTACT: Thomas L. Wegman, President of BioSpecifics Technologies Corp.,
+1-516-593-7000

Web site: http://www.biospecifics.com/